JP2011516840A - 可溶性ｃｄ２００に関するアッセイ法 - Google Patents

可溶性ｃｄ２００に関するアッセイ法 Download PDF

Info

Publication number
JP2011516840A
JP2011516840A JP2011502199A JP2011502199A JP2011516840A JP 2011516840 A JP2011516840 A JP 2011516840A JP 2011502199 A JP2011502199 A JP 2011502199A JP 2011502199 A JP2011502199 A JP 2011502199A JP 2011516840 A JP2011516840 A JP 2011516840A
Authority
JP
Japan
Prior art keywords
soluble
subject
antibody
level
sample
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011502199A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011516840A5 (https=
Inventor
レジナルド エム． ゴーシンスキー
カリー カ ワイ ウォン
Original Assignee
トリリウム セラピューティクス インコーポレーティッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by トリリウム セラピューティクス インコーポレーティッド filed Critical トリリウム セラピューティクス インコーポレーティッド
Publication of JP2011516840A publication Critical patent/JP2011516840A/ja
Publication of JP2011516840A5 publication Critical patent/JP2011516840A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57557—Immunoassay; Biospecific binding assay; Materials therefor for cancer of other specific parts of the body, e.g. brain
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders
    • G01N2800/245—Transplantation related diseases, e.g. graft versus host disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Transplantation (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2011502199A 2008-04-04 2008-07-29 可溶性ｃｄ２００に関するアッセイ法 Pending JP2011516840A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4234208P 2008-04-04 2008-04-04
US61/042,342 2008-04-04
PCT/CA2008/001385 WO2009121162A1 (en) 2008-04-04 2008-07-29 Assay for soluble cd200

Publications (2)

Publication Number Publication Date
JP2011516840A true JP2011516840A (ja) 2011-05-26
JP2011516840A5 JP2011516840A5 (https=) 2011-09-15

Family

ID=41134766

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011502199A Pending JP2011516840A (ja) 2008-04-04 2008-07-29 可溶性ｃｄ２００に関するアッセイ法

Country Status (4)

Country Link
US (2) US8206897B2 (https=)
JP (1) JP2011516840A (https=)
CA (1) CA2720294A1 (https=)
WO (1) WO2009121162A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019084682A1 (en) * 2017-10-30 2019-05-09 Mcmaster University Methods for the diagnosis and treatment of endometriosis
EP4058052A1 (en) * 2019-11-12 2022-09-21 Eli Lilly and Company Cd200 receptor antagonist binding molecules
WO2021243204A1 (en) 2020-05-29 2021-12-02 23Andme, Inc. Anti-cd200r1 antibodies and methods of use thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004513660A (ja) * 2000-11-22 2004-05-13 トリリウム　セラピューティクス　インコーポレーティッド 切断型ｃｄ２００
WO2006020266A2 (en) * 2004-07-20 2006-02-23 Alexion Pharmaceuticals, Inc. Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
JP2007518827A (ja) * 2004-02-02 2007-07-12 シェーリング　コーポレイション Ｃｄ２００およびｃｄ２００ｒを調節する方法
WO2008009711A2 (en) * 2006-07-20 2008-01-24 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of soluble cd160 to suppress immunity

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5401638A (en) 1986-06-04 1995-03-28 Oncogene Science, Inc. Detection and quantification of neu related proteins in the biological fluids of humans
SG10201400426XA (en) 2006-01-12 2014-07-30 Alexion Pharma Inc Antibodies to ox-2/cd200 and uses thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004513660A (ja) * 2000-11-22 2004-05-13 トリリウム　セラピューティクス　インコーポレーティッド 切断型ｃｄ２００
JP2007518827A (ja) * 2004-02-02 2007-07-12 シェーリング　コーポレイション Ｃｄ２００およびｃｄ２００ｒを調節する方法
WO2006020266A2 (en) * 2004-07-20 2006-02-23 Alexion Pharmaceuticals, Inc. Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
WO2008009711A2 (en) * 2006-07-20 2008-01-24 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of soluble cd160 to suppress immunity

Also Published As

Publication number Publication date
US20110052605A1 (en) 2011-03-03
US20120264145A1 (en) 2012-10-18
US8206897B2 (en) 2012-06-26
CA2720294A1 (en) 2009-10-08
WO2009121162A1 (en) 2009-10-08

Similar Documents

Publication Publication Date Title
US11105806B2 (en) Lung cancer markers and uses thereof
US8168586B1 (en) Cancer targets and uses thereof
AU2010295172B2 (en) Methods and compositions for the diagnosis and treatment of thyroid cancer
US8969020B2 (en) Peptide sequence that promotes tumor invasion
US8206897B2 (en) Assay for soluble CD200
KR102401005B1 (ko) 고위험군 자궁내막증의 예방 또는 치료용 조성물
US20190242900A1 (en) A novel invadopodia-specific marker of invasive cancer stem cells and the use thereof
US20190154695A1 (en) Method for detecting and isolating invasive cancer stem cells employing cell-surface amfr and the use thereof
US20240318262A1 (en) Biomarker for predicting prognosis of cancer patient, method for predicting prognosis of cancer patient, method for predicting effect of cancer therapeutic drug in cancer patient, and kit for predicting prognosis of cancer patient
JP2009095343A (ja) 前立腺癌の検出方法及び前立腺癌の術後再発の可能性の判定方法並びに前立腺癌の治療及び／若しくは予防剤
WO2014043331A2 (en) Specific phospho-forms of elk-1 as biomarkers and therapeutic targets for cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110615

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110726

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110726

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120711

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20121226

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20121227

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130527